Showing results (2271-2280 of 6,777) with videos related to

Sort By:
Pageof 678
Clinical Therapeutics|August 27, 2019
"Here Today, Gone Tomorrow" or "Here Today, Stay a Long While": The Divergent Paths of Two Host Factors Important in Viral InfectionsRavi Jhaveri
Clinical Therapeutics|August 27, 2019
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) TrialRichard Haynes, Elsa Valdes-Marquez, Jemma C Hopewell, et al.
Clinical Therapeutics|February 24, 2019
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: Definitions, Similarities, and DifferencesBenjamin H Natelson
Clinical Therapeutics|February 26, 2019
Preoperative Frailty Evaluation: A Promising Risk-stratification Tool in Older Adults Undergoing General SurgeryFred C Ko
Clinical Therapeutics|September 12, 2019
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site AdministrationLindsay M Avery, Iris H Chen, Sergio Reyes, et al.
Clinical Therapeutics|August 14, 2019
Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysisJorge Sanchez-Redondo, Gerard Espinosa, David Varillas Delgado, et al.
Clinical Therapeutics|January 1, 1985
Prospective, randomized comparison of the efficacy and safety of netilmicin-clindamycin and tobramycin-clindamycin in the treatment of serious systemic infectionsS Kahalley, J Chandler, J Hawkins, et al.
Clinical Therapeutics|October 8, 2019
Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of SotagliflozinClaire Ervin, Vijay N Joish, Emily Evans, et al.
Clinical Therapeutics|October 7, 2022
Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United StatesSwapna Karkare, Maryia Zhdanava, Dominic Pilon, et al.
Clinical Therapeutics|March 15, 2011
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childrenBruce E Silverstein, Catherine Allaire, Kirk M Bateman, et al.
Pageof 678